Fundraising Fox

Path EX, Inc.

Houston, US · Delaware corporation · 5 known investors

PATH EX develops CycloPE, an extracorporeal blood purification device that removes bacteria from the bloodstream to treat sepsis in critically ill patients. The technology is designed to integrate with existing ICU workflows and can be used before pathogen identification, targeting both drug-susceptible and drug-resistant bacteria.

BiotechHealthtechMedical Devices

Founders & leadership

SM
Sindead MillerFounder
AW
Alex WieselerinCOO

Board

EJ
Ehsan JabbarzadehBoard director
JB
Jeffrey BurbankBoard director

Investors · 5

Fitz Gate VenturesHouston · $500K – $1M
Houston Angel NetworkHouston
Innova Memphis, Inc.Memphis · $2M
Texas HALO FundHouston
TMC Venture FundHouston

Reported raises · per SEC filings

Form D private placements

$8.3M disclosed across 2 rounds · 2017–2025

▶$8.2MraisedMay 2025 · 14 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Sindead MillerExecutive Officer, Director
  • Ehsan JabbarzadehDirector
  • Jeffrey BurbankDirector
Offering amount
$8.2M
Amount sold
$8.2M
First sale
Apr 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$100KraisedMay 2017 · 2 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Sinead MillerExecutive Officer, Director
  • Alex WieselerExecutive Officer, Director
Offering amount
$100K
Amount sold
$100K
First sale
May 2017
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 2

by search overlap
Thumbnail for SyntheX5 shared keywordsSyntheX develops the ToRFLEx platform, a first-in-class drug discovery technology that enables screening for compounds that modulate protein-protein interactions and targeted protein degradation for previously inaccessible drug targets identified by geneticists. The company builds an internal oncology pipeline and partners with external organizations to expand adoption of its platform.
ARTHEx Biotech’s website4 shared keywordsArthex Biotech develops antisense RNA compounds to treat diseases with unmet medical needs. The company focuses on microRNA-based therapeutic interventions.

Companies competing with Path EX, Inc. for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 2 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Science FoundationPhase II2018$750K
National Science FoundationPhase ISTTR2017$225K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does Path EX, Inc. do?
PATH EX develops CycloPE, an extracorporeal blood purification device that removes bacteria from the bloodstream to treat sepsis in critically ill patients. The technology is designed to integrate with existing ICU workflows and can be used before pathogen identification, targeting both drug-susceptible and drug-resistant bacteria.
Who founded Path EX, Inc.?
Path EX, Inc. was founded by Sindead Miller.
Who are Path EX, Inc.'s investors?
Path EX, Inc.'s investors include Fitz Gate Ventures, Houston Angel Network, Innova Memphis, Inc., Texas HALO Fund, TMC Venture Fund.
How much funding has Path EX, Inc. raised?
Path EX, Inc. has disclosed $8.3M raised across 2 rounds.
Where is Path EX, Inc. headquartered?
Path EX, Inc. is headquartered in Houston, US.